For Watson CEO Bisaro, “Operational Efficiency” Is An Industry-Wide Calling
Executive Summary
Contaminated heparin continues to create regulatory fallout worldwide, so one might think that this would not be a particularly good time to press FDA to loosen its manufacturing oversight
You may also be interested in...
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs
FDA's Office of Generic Drugs is poised to enter a new era with new leadership, even as the agency is saying it will draw on the expertise of veteran officials for key initiatives
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Problems at a drug company have once again put FDA in the crosshairs of the House Energy and Commerce Committee
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Problems at a drug company have once again put FDA in the crosshairs of the House Energy and Commerce Committee